Cambridge Investment Research Advisors, Inc. Crispr Therapeutics Ag Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 24,302 shares of CRSP stock, worth $994,923. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,302
Previous 28,540
14.85%
Holding current value
$994,923
Previous $1.54 Million
25.89%
% of portfolio
0.0%
Previous 0.01%
Shares
24 transactions
Others Institutions Holding CRSP
# of Institutions
490Shares Held
58MCall Options Held
1.1MPut Options Held
1.9M-
Capital International Investors Los Angeles, CA7.93MShares$325 Million0.07% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.5MShares$307 Million3.35% of portfolio
-
State Street Corp Boston, MA2.99MShares$123 Million0.01% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.2.97MShares$122 Million0.1% of portfolio
-
Nikko Asset Management Americas, Inc.2.97MShares$121 Million1.61% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.19B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....